10-Q: Coherus Oncology Reports Q2 2026 Results, Faces Cash Burn

Coherus Oncology's Q2 2026 Form 10-Q reveals continued operational losses and a significant decrease in cash reserves, though LOQTORZI sales show growth.

Summary

• Coherus Oncology reported a net loss of $20.6 million for the three months ended June 30, 2026, and a net loss of $58.9 million for the six months ended June 30, 2026.
• Total net revenue for the three months ended June 30, 2026, was $14.3 million, an increase from $10.3 million in the prior year period, primarily driven by LOQTORZI sales.
• Cash, cash equivalents, and marketable securities decreased to $105.3 million as of June 30, 2026, from $172.1 million at December 31, 2025.
• The company continues to rely on external funding, stating that its current cash reserves are not expected to be sufficient to fund clinical trials through commercialization.
• The company divested its UDENYCA franchise in April 2025 and is eligible for two additional payments of $37.5 million each, which have not yet been met.
• Research and development expenses decreased to $21.4 million for the three months ended June 30, 2026, from $26.3 million in the prior year period.
• Selling, general, and administrative expenses also decreased to $21.0 million for the three months ended June 30, 2026, from $26.0 million in the prior year period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued net losses, significant cash burn from operations, and reliance on future funding, despite some revenue growth for LOQTORZI.

Positives

• LOQTORZI net revenue increased to $13.6 million for the three months ended June 30, 2026, up from $10.0 million in the same period last year.
• Gross margin improved to 70% for the three and six months ended June 30, 2026, compared to 67% and 66% respectively in the prior year periods.
• Selling, general, and administrative expenses decreased by $5.1 million for the three months ended June 30, 2026, compared to the prior year period.
• Research and development expenses decreased by $4.9 million for the three months ended June 30, 2026, compared to the prior year period.

Negatives

• The company reported a net loss of $20.6 million for the three months ended June 30, 2026, and a net loss of $58.9 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and marketable securities decreased by $66.8 million to $105.3 million as of June 30, 2026.
• Net cash used in operating activities was $119.9 million for the six months ended June 30, 2026.
• The company has an accumulated deficit of $1.4 billion as of June 30, 2026.
• The company acknowledges that its current cash reserves are insufficient to fund clinical trials through commercialization and will require additional funding.
• The company did not meet the earnout thresholds for the UDENYCA sale as of June 30, 2026.

Risks

• The company has a limited history of profitability and may not achieve profitability again.
• Continued dependence on raising funds, with no assurance that additional funding will be available on acceptable terms.
• Commercial success of LOQTORZI depends on market acceptance, physician adoption, and third-party payer coverage and reimbursement.
• Product candidates face significant competition from other immuno-oncology biologics and treatment regimens.
• Healthcare reform measures, such as the Inflation Reduction Act, may increase difficulty and cost of obtaining marketing approval and commercialization.
• Reliance on key executives and personnel; failure to retain them could harm the business.
• Reliance on third-party contract manufacturers and research organizations, with potential for disruptions or failure to meet obligations.
• Manufacturing risks, including potential cost increases and supply limitations, especially with the transition to an onshoring business model.

Future Outlook

The company expects net revenue from continuing operations in 2026 to be higher than in 2025 due to continued growth of LOQTORZI. They also expect fixed R&D expenses in 2026 to be lower than in 2025 due to reduced expenditures on manufacturing development and headcount. SG&A expenses are also expected to be lower for the full year 2026 compared to 2025 due to decreased operating costs and headcount. Interest expense is expected to remain comparable.

Management Comments

• Management believes that its available cash, cash equivalents and marketable securities, and product sales will be sufficient to fund its planned expenditures and meet its obligations for at least the twelve months following the financial statement issuance date.
• The company will need additional funding to support its continuing operations and pursue its long-term business plan.
• Management expects continued growth of LOQTORZI sales in 2026.

Industry Context

StockSavvy.ai notes that Coherus Oncology operates in the highly competitive oncology market, facing established players with significant resources. The company's strategy of focusing on LOQTORZI and advancing its pipeline candidates aligns with industry trends of developing targeted immunotherapies, but the path to profitability remains challenging given the high costs of drug development and market competition.

Comparison to Industry Standards

• Coherus Oncology's net loss of $20.6 million for the quarter and $58.9 million for the six months is substantial, reflecting the high R&D and SG&A costs typical in the biopharmaceutical industry, especially for companies developing novel oncology treatments.
• The company's cash burn rate of $119.9 million for six months is significant, but not unusual for companies in clinical development or early commercialization stages in the biotech sector, where substantial investment is required before achieving profitability.
• The revenue growth for LOQTORZI, while positive, is from a relatively small base compared to established blockbuster drugs in the oncology space, indicating a need for significant market penetration and sales growth to offset operational costs.

Legal Proceedings

• The company's 2023 tax year is under examination by the Internal Revenue Service.

Related Party Transactions

• The company has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to the company's financial performance and reliance on future funding.
• Employees may face uncertainty regarding job security if the company's financial situation deteriorates or if further cost-cutting measures are implemented.
• Creditors and debt holders face increased risk given the company's accumulated deficit and ongoing cash burn.

Next Steps

• Continue to grow sales of LOQTORZI in Nasopharyngeal Carcinoma (NPC).
• Advance the development of pipeline candidates (casdozokitug and tagmokitug) in combination with LOQTORZI or other agents.
• Execute ex-U.S. licensing deals for clinical-stage candidates as clinical data supports.
• Evaluate tagmokitug in combination with pasritamig in a Phase 1b clinical study expected to initiate in fall 2026.
• Continue to manage R&D and SG&A expenses to lower levels.

Key Dates

Recommendation

While LOQTORZI shows revenue growth, the company's significant net losses, substantial cash burn, and explicit need for future funding present considerable risk. The current cash position, though sufficient for the next 12 months, is declining, and the company has not yet met earnout targets from prior divestitures. The competitive landscape in oncology is intense. A 'hold' recommendation reflects the potential for future growth if pipeline candidates succeed and LOQTORZI gains market traction, balanced against the significant financial risks and execution challenges.

Keywords

oncology, LOQTORZI, toripalimab, PD-1 inhibitor, clinical trials, drug development, pharmaceutical, biotechnology